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Summary: We assessed the prevalence of epilepsy in an 
elderly population in The Netherlands. The study was 
conducted from 1991 to 1993 as part of the Rotterdam 
Study, a population-based door-to-door study of all elder­
ly people living in Ommoord, a suburb of Rotterdam, and 
included 5,559 persons aged 55-95 years. All subjects 
were screened for epilepsy through direct questions re­
garding the existence of epilepsy and antiepileptic drug 
(AED) use, in addition to relevant questions from the 
World Health Organization (WHO) protocol for epidemi­
ologic studies of neurologic diseases. Further evaluation 
of screen positives was made by a panel of 1 study phy­
sician and 4 epileptologists, who also classified all con­
firmed cases of epilepsy according to the classifications of
the International League Against Epilepsy (ILAE), The 
overall prevalence of active epilepsy in our study popu­
lation was 0.9% including special syndromes and 0.8% 
excluding special syndromes. The prevalence increased 
with age from 0.7% for those aged 55-64 years to 1.2% for 
those aged 85-94 years. The increase with age was de­
tected among men and women both. Our study confirms 
other findings showing that the prevalence of active epi­
lepsy increases with age in the elderly. The prevalence 
figures in our study were high as compared with those of 
other population-based studies. Epilepsy appears to be a 
major cause of morbidity in the elderly. Key Words: Ep­
ilepsy—Population studies—Prevalence—Screening— 
Seizures.
The prevalence of epilepsy in the elderly has been 
investigated in only a few studies. Hauser and 
Kurland (1,2) and Tallis et al. (3) reported that the 
prevalence and incidence of epilepsy increase with 
age, but this was not confirmed by other investiga­
tors (4,5). In a large primary-care-based study of 
people aged 5=60 years in the United Kingdom, Tal­
lis et al. reported an increase in age-adjusted prev­
alence and incidence figures of epilepsy, making it 
the third most common neurological disorder (after 
stroke and dementia) in this age group (3), We 
wished to assess the prevalence of epilepsy in an 
elderly Dutch population.
METHODS
Study population
The investigation was conducted as part of the 
ongoing Rotterdam Study, a prospective follow-up
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survey of the total population aged ^55 years in the 
district of Ommoord in Rotterdamthe Netherlands 
(6). The baseline survey took place from June 1990 
until June 1993. Informed consent and permission 
to obtain relevant information from treating physi­
cians were obtained from all participants. Through­
out the Rotterdam Study, subjects were surveyed in 
random clusters. Epilepsy screening was incorpo­
rated at the time of the 25th random survey in June 
1991. The total eligible population consisted of 
7,129 persons. Because the number of subjects aged 
5*95 years was to small to determine an accurate 
prevalence figure, we excluded this age group from 
our analysis, Therefore our total eligible population
consisted of,7,081 persons, 5,559 (79%) of whom 
participated in the epilepsy screening.
Screening for epilepsy
The standard Rotterdam Study protocol con­
sisted of a home interview followed by physical ex­
aminations in a research center. The screening for 
epilepsy was conducted during the home interview 
by a trained research assistant and consisted of one
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question directly inquiring about epilepsy (Have 
you ever experienced epilepsy or had an epileptic 
fit?) and three questions regarding possible symp­
toms of epilepsy that were taken from the World 
Health Organization (WHO) research protocol for 
the screening of neurological disorders in develop­
ing countries (7), as follows: Have you ever lost 
consciousness? Have you ever had episodes where 
you lost contact with your surroundings? and Have 
you ever had any shaking of your arms and legs 
which you could not control? In addition, all cur­
rent drug prescriptions were registered and classi­
fied according to the Anatomical Therapeutic 
Chemical (ATC) classification index (8). We de­
fined as screen-positive for epilepsy all persons who
(a) self reported epilepsy or fits, or (b) used antiep­
ileptic drugs (AEDs: ATC-code N03), or (c) an­
swered yes to at least two of the three WHO ques­
tions .
Diagnostic workup and classification of epilepsy
For persons who reported having had epilepsy or 
seizures during their life (n = 97), as well as for 
persons receiving AEDs without reporting epilepsy 
(n = 24), additional information was obtained from 
general practitioner’s and specialists’ medical 
records, including EEG and computed tomography 
(CT) scan reports. For 22 subjects, no further infor­
mation was available from medical records and they 
were contacted by telephone by a specially trained 
physician who took a detailed medical and seizure 
history. A similar procedure was used for subjects 
who gave positive responses to at least two of the 
WHO screening questions but who neither reported 
having epilepsy or receiving AEDs (n = 192). Per­
sons without a telephone, those who did not answer 
the telephone on several occasions, and those who 
were unable to give a reliable history by telephone 
were invited to an in-person interview, either in 
their home or at the research center. If the history 
suggested the possibility of epilepsy, the subject
was reinterviewed by 1 of 4 epileptologists (Drs. 
D. J. Beintema, C. A. E. H. van Oorschot, A. van 
Wieringen, and J. M. de Wilde-Ockeloen), and ad­
ditional information was obtained from the general 
practitioner and other medical records.
All 313 screen-positive persons were subse­
quently reviewed by a panel consisting of the study 
physician and the 4 epileptologists. From all avail­
able information, the panel then decided whether a 
subject had epilepsy and, if so, classified the epi­
lepsy according to the classification of the Interna­
tional League Against Epilepsy (ILAE) (9). Single 
seizures, treated or not, were classified as “ epi­
lepsy-special syndromes5’ according to 1989 ILAE 
guidelines (9). Active epilepsy was defined as hav­
ing had a seizure within 5 years of prevalence date, 
regardless of treatment (10).
Data analysis
Prevalence was calculated by gender and 10-year 
age groups. We calculated the prevalence of active 
epilepsy and of lifetime epilepsy, which includes 
both active epilepsy and epilepsy in remission. 
Prevalence of active epilepsy was calculated both 
including and excluding special syndromes. To 
compare our results with those of other published 
studies, we also calculated the age-specific preva­
lences of active epilepsy, defined as having had a 
seizure within 5 years of prevalence date or current 
use of AEDs. The proportion of each ILAE subtype 
of epilepsy was reported by gender.
RESULTS
Table 1 shows the age and gender distribution of 
the study population and the number of screen- 
positive individuals. Of the total population of 5,559 
persons screened, 313 persons (5.6%) were screen 
positive. No screen-positive men were in the high­
est age category. Overall, 97 (1.7%) persons re­
ported epilepsy, 24 (0.4%) received AEDs without
TABLE 1. Age distributìon and screening results of thè study population
Age groups (yr)
Parameter 55-64 65-74 76-84 85-94 Total
No. of subjects 2,125 1,916 1,105 413 5,559
Proportion of women (%) 56 55 65 80 59
No. with self-reported epilepsy (%) 38 (1,7) 37 (1.9) 14(1.3) 8(1.9) 97 (1.7)
No. receiving AEDs (%)a 19 (0.9) 23 (1.2) 13 (1.2) 6(1.5) 61 (1.1)
No. of WHO screen positives (%)fa 97 (4.6) 80 (4.2) 45 (4.1) 15 (3.6) 237 (4.3)
No. of screen positives (%)c 121 (5.7) 115 (6.0) 56 (5.1) 21 (5.1) 313 (5.6)
AED, antiepileptic drug; WHO, World Health Organization. 
a Regardless of self-reported epilepsy.
b Regardless of self-reported epilepsy and AED use: defined as having answered positively to at least two of the three WHO screening 
questions on epilepsy. 
c Defined as self-reported epilepsy or AED use or WHO screen positive.
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TABLE 2. Results of verification for all
screen-positive subjects
Final diagnosis
Screen-positive
categories Epilepsy
No
epilepsy Missing Total
Self-reported epilepsy 
AED use without 
self-reported
70 20 7 97
epilepsy 
WHO screen positive0 
without 
self-reported 
epilepsy or AED
4 20 0 24
use 11 180 1 192
Total 85 220 8 313
Abbreviations as in Table 1.
° Defined as having answered positively to at least two of the three 
WHO screening questions on epilepsy.
TABLE 4. Summary of spécial syndromes in the
Rotterdam Study
Etiology 
(no. of subjects) Associated condition
Acute symptomatic (7)
Remote symptomatic (3)
Cryptogenic (10)
Total (20)
Eclampsia, acute CVA, fever, 
influenza encephalitis, alcohol 
withdrawal (2), cerebral anoxia 
CVA >1 year before seizure, 
Parkinson’s disease, subdural 
hematoma 
Abnormal EEG or CT scan; no 
known antecedent cause (5); 
no abnormality on EEG or CT 
scan; no known antecendent 
cause (5)
CVA, cerebrovascular accident; CT, computed tomography.
reporting epilepsy, and 192 (3.5%) persons were 
screen positive because of positive answers to the 
WHO questions even though they did not report 
epilepsy or treatment with AEDs.
Table 2 shows results after verification of all 
screen-positive subjects. We confirmed 85 cases of 
epilepsy, or 27% of all screen positives. For 27 per­
sons (28%) who reported epilepsy, the diagnosis 
could not be confirmed. Eleven cases showed clear 
evidence from neurologists’ records for a nonepi­
leptic cause of symptoms; sleep apnea, transient 
ischemic attack (n = 2), depression, psychogenic 
attacks (n = 2), muscle headaches, narcolepsy, 
amaurosis fugax with migraine, nocturnal urinary 
incontinence, and syncope. For the remaining 16 
persons, no information regarding possible epilepsy 
or other paroxysmal disorder could be detected. 
Nine of them were reinterviewed by 1 of the epilep- 
tologists, who made a specific nonepilepsy diagno­
sis. No further information could be obtained in 7 
individuals. Of the 24 subjects who received AEDs 
without reporting epilepsy, we concluded that only
4 had epilepsy. The reasons for treatment with 
AEDs for conditions other than epilepsy were di­
verse; 3 persons were prescribed clonazepam for 
restless legs syndrome, 7 persons received carba- 
mazepine (CBZ) for trigeminal or hypoglossal neu­
ralgia, 1 subject received CBZ for manic-depressive 
psychosis; 1 was prescribed valproate (VPA) pro- 
phylactically after herpes encephalitis without clin­
ical or EEG evidence of epilepsy, 5 persons with 
mental disorders were long-term barbiturate users, 
2 persons were prescribed CBZ for polyneuropa­
thy, and 1 subject could not be verified as an AED  
user.
Table 3 summarizes the types of epilepsies for 
both active and lifetime epilepsy and for men and 
women. Localization-related epilepsy was the most
TABLE 3. Subclassification of epilepsies according to the ILAE
Epilepsy type according to ILAE classification
Active epilepsy, 
no. of subjects
(%)
Men Women
Lifetime epilepsy, 
no. of subjects
(96)
Men Women
I Localization-related epilepsies 17 (73.9) 18 (64.3) 19 (55.9) 21 (41.2)
1-1 Idiopathic 0 0 0 0
1-2 Symptomatic 10 8 11 10
1-3 Cryptogenic 7 10 8 11
II Generalized epilepsies 1 (4.4) 2(7.1) 3 (8.8) 2 (3.9)
II-1 Idiopathic 0 1 1 1
II-2 Cryptogenic or symptomatic 0 0 0 0
II-3 Symptomatic 1 1 2 1
III Epilepsies undetermined whether focal or generalized 0 (0.0) 4 (14.3) 4 (11.8) 16(31.4)
III-l With both focal and generalized seizures 0 0 0 0
III-2 Undetermined seizure type 0 4 4 16
IV Special syndromes 5 (21.7) 4 (14.3) 8 (23.5) 12 (23.5)
IV-1 Single seizure, not followed by treatment with AEDs 1 2 3 6
IV-2 Single seizure, followed by treatment with AEDs 4 2 5 6
Total 23 (100%) 28 (100%) 34 (100%) 51 (100%)
ILAE, International League Against Epilepsy; AEDs, antiepileptic drugs.
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TABLE 5. Prevalence of lifetime and activea epilepsy by gender and age [cases per 1,000 (no. of cases)]
10-Year 
age group
Men Women
No. of 
subjects
Including special 
syndromes
Excluding special 
syndromes
No. of 
subjects
Including special 
syndromes
Lifetime Active Lifetime Active Lifetime Active
55-64 932 13.9(13) 6.4 (6) 9.7 (9) 4.3 (4) 1,193 16.8 (20) 7.5 (9)
65-74 855 16.4(14) 11.8(11) 12.9 (11) 10.5 (9) 1,061 17.0 (18) 7.5 (8)
75-84 390 17.9 (7) 15.4 (6) 15.4 (6) 12.8 (5) 715 9.8 (7) 8.4 (6)
85-94 83 0 0 0 0 330 18.2 (6) 15,2 (5)
Total 2,260 15.0 (34) 10.2 (23) 11.5 (26) 8.0 (18) 3,299 15,5 (51) 8.5 (28)
Women
•
All
Excluding special Including special Excluding special
10-Year
syndromes
No. nf
syndromes syndromes
age group Lifetime Active subjects Lifetime Active Lifetime Active
55-64 12.6 (15) 7,5 (9) 2,125 16.0 (33) 7.1 (15) 11.3 (24) 6.1 (13)
65-74 12.3 (13) 6.6 (7) 1,916 16.2 (32) 9.9 (19) 12.5 (24) 8.4 (16)
75-84 8.4 (6) 7.0 (5) 1,105 12.7 (14) 10.9 (12) 10.9 (12) 9.0 (10)
85-94 15.2 (5) 12.1 (4) 413 14.5 (6) 12.1 (5) 12.1 (5) 9.7 (4)
Total 11.8 (39) 7.6 (25) 5,559 15.3 (85) 9.2 (51) 11.7(65) 7.7 (43)
a Defined as at least one seizure within 5 years of prevalence date, regardless of treatment.
common type in both men and women. The second 
most common type of active epilepsy in men was 
special syndrome, whereas in women it was both 
undetermined epilepsy and special syndrome. Gen­
eralized epilepsy was relatively uncommon in both 
sexes.
Table 4 summarizes all special syndromes. Of the 
20 cases detected, 7 were acute symptomatic sei­
zures, 3 of which were subsequently treated with 
AEDs [stroke, alcohol withdrawal (n = 2)]. Three 
patients with remote symptomatic epilepsy were 
detected, all of whom received AEDs. The remain­
ing 10 patients had no determinable antecedent 
cause, but 5 of them had abnormalities on EEG or 
CT scan; 1 of the 5 patients subsequently was 
started on AED treatment. Four of the 5 remaining 
subjects with no abnormality on EEG or CT scan 
were treated with AEDs.
The prevalence figures of epilepsy are shown in 
Table 5. We noted an overall lifetime prevalence of 
epilepsy in this 55-95-year-old population of 15.3
cases in 1,000 and an overall prevalence of active 
epilepsy of 9.2 cases in 1,000. The prevalence of 
active epilepsy increased with advancing age, but 
the prevalence of lifetime epilepsy leveled off or 
even decreased in the highest age groups. When we 
excluded special syndromes, the overall prevalence 
for active epilepsy was 7.7 cases per 1,000 persons. 
When we included subjects treated with AEDs in 
the definition of active epilepsy, regardless of 
whether they had had a seizure in the last 5 years, 
the prevalence figures increased slightly (Table 6).
DISCUSSION
We screened a large elderly population and de­
termined the prevalence of active and lifetime epi­
lepsy in the group. The prevalence figures for active 
epilepsy were among the highest reported in the 
literature among elderly persons. Only Hauser et al. 
reported a higher rate for active epilepsy in persons 
aged >75 years (2).
TABLE
10-Year 
age group
Men Women All
No. of 
subjects
Including
special
syndromes
Excluding
special
syndromes
No. of 
subjects
Including
special
syndromes
Excluding
special
syndromes
No. of 
subjects
Including
special
syndromes
Excluding
special
syndromes
55-64 932 8,6 6.4 1,193 9.2 8.4 2,125 8.9 7.5
65-74 855 14.0 11.7 1,061 9.4 8.5 1,916 11.5 9.9
75-84 390 15.4 12.8 715 8.4 7.0 1,105 10.9 9,0
85-94 83 0.0 0.0 330 18.2 15.2 413 14.5 12.1
Total 2,260 11.5 9.3 3,299 o o 8.8 5,559 10.6 9.0
Active epilepsy defined as at least one seizure within 5 years of prevalence date or antiepileptic drug use.
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TABLE 7. Prevalence of epilepsy in elderly subjects: A comparison of recent studies
Age
Prevalence
Study size 
(age, yr)
(cases per 1,000)
Criteria used to define epilepsy 
and activeness of epilepsy
Country
(reference)
group
(yr)Year Study design Active Lifetime
Rotterdam, The 1994 Population based; WHO N = 5,559 55-64 6.1 7.5 11.3 Recurrent seizures, provoked and
Netherlands screening protocol (55+) 65-74
75-84
85-94
8.4 9.9 
9.0 9.0 
9.7 12.1 
to
12.5
10.9
12.1
unprovoked; active defined as 
having had at least one seizure 
in the past 5 years regardless of 
treatment (column 1) or having 
had at least one seizure in the 
past 5 years or current 
treatment (column 2)
Rochester, 1991 Register based; total N - 56,447 55-64 7.7 9.8 Recurrent unprovoked seizures;
MN, U.S.A. population of Rochester (all ages) 65-74 6.8 8.1 active defined as having had at
(2) 75 + 14.8 16.9 least one seizure in the past 5 
years or having had AED 
treatment in the past 5 years
United Kingdom 1991 Register based; N = 81,727 60-69 — 10.9 No distinction between provoked
(3) computerized general 
practice database
(60+) 70-79 
80 + —
12.0
13.1
or unprovoked seizures; no 
distinction between active 
epilepsy or epilepsy in 
remission
Ecuador (18) 1992 Population based; N = 10,948 50-59 11.7 21.2 Single or recurrent seizures,
study-specific screening (50+) 60-69 6.6 16.4 provoked and unprovoked,
protocol 70-98 8.2 14.2 excluding febrile seizures; 
active epilepsy defined as 
having had a seizure in the past 
year and/or receiving AED at 
the time of the study
China (4) 1985 Population based; WHO N - 14,173 50-59 — 3.4 Recurrent unprovoked seizures;
screening protocol (50 + ) 60-69 
70 +
3.9
2.9
no distinction between active 
and lifetime prevalence
India (13) 1988 Population based; WHO N = 8,071 40-59 3.4 3.9 Recurrent unprovoked seizures;
screening protocol (40+) 60 + 3.5 4.3 active epilepsy defined as 
having had at least one seizure 
in the past 5 years regardless of 
treatment
Nigeria (11) 1987 Population based; WHO N - 18,954 35-54 4.5 — Recurrent unprovoked seizures; if
screening protocol (all ages) 55 + 4.8 previously untreated, having 
had at least one seizure in the 
past 2 years and if under 
treatment having had at least 
one seizure in the past 3 years
Tunesia (12) 1993 Population based; WHO N - 3,460 50-59 0.5 - Recurrent unprovoked seizures;
screening protocol (50 + ) 60+ 3.1 active defined as having had at 
least one seizure in the past 5 
years or having had treatment 
in the past 5 years
Copiah 1986 Population based; N = 8,925 40-59 8.8 13.1 Recurrent unprovoked seizures;
county, study-specific screening (40 + ) 60 + 5.1 8.4 active defined if under
U.S.A. (19) protocol treatment as having had at least 
one seizure in the past 3 years 
and if untreated having had a 
seizure in the past year
Sweden (5) 1992 Register based; N = 52,792 50-59 6.4 - Recurrent unprovoked seizures;
multisource medical (50+) 60-69 6.2 - active defined as having had at
registers 70+ 3,2 least one seizure in the past 5 
years or receiving AEDs in the 
year preceding prevalence date
Italy (20) 1983 Register based; medical N = 45,153 40-59 4.6 - Recurrent unprovoked seizures;
and nonmedical (all ages) 60 + 3.0 - active defined as having had at
registers least one seizure in the last 5 
years or receiving AEDs
United 1983 Register based; register of N = 1,581 50-60 a 11.8 Provoked and unprovoked
Kingdom (21) one general practice (51+) 61-70 
71-80 
80 +
24.1
26.2 
10.6
seizures excluding febrile 
seizures; active defined as 
having had at least one seizure 
in the past 2 years
AEDs, antiepileptic drugs.
a Only an overall prevalence figure for active epilepsy was given; 5.3 in 1,000.
Our study has several possible limitations. First, 
despite our best efforts, we were unable to obtain 
100% participation. Although our participation rate 
was high given the age distribution of our study
population, the prevalence of epilepsy may be dif­
ferent among nonparticipants as compared with 
participants. A second issue concerns the sensitiv­
ity of our screening questions. The screening instru-
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ment we used contained direct questions regarding 
epilepsy and current drug use, in addition to ques­
tions that were adapted from the WHO protocol 
originally designed for neuroepidemiological stud­
ies in developing countries (7). Other studies have 
also used this protocol to screen for epilepsy (4,11- 
13). Nonetheless, although high sensitivities have 
been reported, the instrument has never been vali­
dated properly (14). We did not include a sample of 
screen negatives because the prevalence among 
screen negatives is likely to be much lower than that 
in the total study population, and to obtain a stable 
and precise estimate of the prevalence among 
screen negatives, a very large sample would have 
been required. Therefore, we may have missed 
some cases of epilepsy, especially persons with par­
tial seizures. Finally, Alzheimer’s disease is a rec­
ognized risk factor for late-onset epilepsy (15,16). 
Because of underreporting of seizures and symp­
toms in demented patients, we may have missed 
some patients with both dementia and epilepsy. 
These various considerations make it likely that our 
prevalence figures are slight underestimates.
Comparisons among studies must take into ac­
count variations in methods and definitions (2). Ta­
ble 7 compares the results of our study with those of 
several other recent investigations which provided 
age-specific prevalences of epilepsy. We classified 
special syndromes as epilepsy according to the 1989 
ILAE classification (9). The rationale of including 
special syndrome is debatable, however. Most 
acute symptomatic seizures are clearly not epi­
lepsy, and some subjects who immediately receive 
treatment with AEDs after a first cryptogenic or 
remote symptomatic seizure may or may not de­
velop epilepsy subsequently. Furthermore, single 
seizures that occurred long ago are likely to be un­
derreported. To enhance comparability, we report 
rates for active and lifetime epilepsy that exclude 
the special syndromes.
Few investigators have reported age-specific 
prevalence figures for active epilepsy in the elderly, 
and those that did generally provided rates consid­
erably lower than those we report. Screening for 
epilepsy relies on a willingness to report epilepsy or 
seizures or related symptoms. In the Rotterdam 
Study, screening for epilepsy was conducted as part 
of a much larger investigation of other diseases rel­
evant to aging and the participation rate was high
(6). This study context may have contributed to our 
identifying a large number of patients. For lifetime 
prevalence, however, our estimates are relatively 
low, in particular as compared with estimates from 
register-based studies. Because remission rates are 
estimated to exceed 61% at 10 years after of epi­
lepsy onset (17), population-based studies of the 
lifetime prevalence of epilepsy may well suffer from 
recall bias and underreporting, resulting in consid­
erable underestimation, especially in the elderly. 
Besides, what researchers truly wish to ascertain is 
the cumulative incidence. Because mortality is in­
creased among subjects with epilepsy, as compared 
to subjects without epilepsy, lifetime prevalence 
will always underestimate cumulative incidence.
The results of our study confirm earlier findings 
indicating that the prevalence of active epilepsy in­
creases with age in the elderly. The prevalence fig­
ures in our study were high as compared with those 
of other population-based studied. Epilepsy ap­
pears to be a major cause of morbidity in the el­
derly .
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